289717-61-9Relevant academic research and scientific papers
Synthesis and biological activity of piperazine and diazepane amides that are histamine H3 antagonists and serotonin reuptake inhibitors
Ly, Kiev S.,Letavic, Michael A.,Keith, John M.,Miller, Jennifer M.,Stocking, Emily M.,Barbier, Ann J.,Bonaventure, Pascal,Lord, Brian,Jiang, Xiaohui,Boggs, Jamin D.,Dvorak, Lisa,Miller, Kirsten L.,Nepomuceno, Diane,Wilson, Sandy J.,Carruthers, Nicholas I.
, p. 39 - 43 (2008/09/17)
The synthesis and biological activity of a new series of piperazine and diazepane amides is described. The new compounds are high affinity histamine H3 ligands and serotonin reuptake inhibitors.
BUTYL AND BUTYNYL BENZYL AMINE COMPOUNDS
-
Page/Page column 12, (2008/06/13)
Certain substituted butyl and butynyl benzyl amine compounds are histamine H3 receptor and/or serotonin transporter modulators useful in the treatment of histamine H3 receptor- and/or serotonin-mediated diseases.
SUBSTITUTED BENZYL AMINE COMPOUNDS
-
Page/Page column 35, (2008/06/13)
Certain substituted benzyl amine compounds are histamine H3 receptor and/or serotonin transporter modulators useful in the treatment of histamine H3 receptor- and/or serotonin-mediated diseases.
SUBSTITUTED AMINOMETHYL BENZAMIDE COMPOUNDS
-
Page/Page column 30, (2008/06/13)
Certain substituted aminomethyl benzamide compounds are histamine H3 receptor and/or serotonin transporter modulators useful in the treatment of histamine H3 receptor- and/or serotonin-mediated diseases.
Benzylamine histamine H3 antagonists and serotonin reuptake inhibitors
Letavic, Michael A.,Stocking, Emily M.,Barbier, Ann J.,Bonaventure, Pascal,Boggs, Jamin D.,Lord, Brian,Miller, Kirsten L.,Wilson, Sandy J.,Carruthers, Nicholas I.
, p. 4799 - 4803 (2008/03/11)
The design, synthesis, and in vitro activity of a series of novel 5-ethynyl-2-aryloxybenzylamine-based histamine H3 ligands that are also serotonin reuptake transporters is described.
Monoamine reuptake inhibitors for treatment of CNS disorders
-
, (2008/06/13)
The present invention relates to compounds of the formula wherein R1through R4, X, Y, m and n are defined as in the specification. Such compounds are useful exhibit activity as serotonin, norepinephrine and dopamine reuptake inhibito
Combination treatment for alcoholism and alcohol dependence
-
, (2008/06/13)
The present invention relates to a method of treating alcoholism or alcohol dependence in a mammal, including a human, by administering to the mammal a monoamine reuptake inhibitor in combination with an opioid antagonist. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, a monoamine reuptake inhibitor and an opioid antagonist.
Combination treatment for sleep disorders including sleep apnea
-
, (2008/06/13)
The present invention relates to a method of treating sleep disorders including sleep apnea in a mammal, including a human, by administering to the mammal a 5HT1a antagonist or an alpha-2-adrenergic antagonist in combination with an SRI antidepressant agent with improvement in efficacy. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, a 5HT1a antagonist or an alpha-2-adrenergic antagonist, and an SRI antidepressant agent.
Combination treatment for anxiety and depression
-
, (2008/06/13)
The present invention relates to a method of treating depression or anxiety in a mammal, including a human, by administering to the mammal a GABA-A alpha ? agonist in combination with an SRI antidepressant agent with improvement in efficacy. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, a GABA-A alpha ? agonist, and an SRI antidepressant agent.
Combination treatment for depression
-
, (2008/06/13)
The present invention relates to a method of treating depression, especially refractory depression, in a mammal, including a human, by administering to the mammal a sigma receptor ligand in combination with an antidepressant agent. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, a sigma receptor ligand and a serotonin reuptake inhibitor.
